Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April
15 March 2023 - 9:00AM
Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the
discovery and development of antibody-based therapies, today
announced poster presentations at the upcoming AACR Annual Meeting
in Orlando, Florida from April 14-19, 2023.
Two poster presentations on ADG126 SAFEbody will
report results of ongoing phase 1b/2 trials of this masked,
anti-CTLA-4 therapy in combination with two different anti-PD-1
treatments at multiple dosing regimens (6 mg/kg and 10 mg/kg).
Following an interim update in January reporting compelling safety
and confirmed clinical responses for ADG126 combo with toripalimab,
detailed results will be presented along with updated data for
ADG126 monotherapy in heavily pre-treated patients. Notably, the
results of ADG126 in combination with pembrolizumab after repeated
dosing to assess late-onset toxicity will also be presented for the
first time.
The third poster will review the differentiated preclinical
profile of ADG153, an anti-CD47 SAFEbody® in IgG1 isotype,
currently in the IND-enabling stage. As expected, IgG1 isotype of
masked anti-CD47, ADG153, enables monotherapy efficacy for solid
tumors due to strong antibody-dependent cellular cytotoxicity
(ADCC) and enhanced antibody-dependent cellular phagocytosis (ADCP)
effects, while masking anti-CD47 in IgG1 can overcome the safety
challenges of CD47- therapies, particularly for potent
IgG1-mediated tumor killing proven for both solid and liquid
tumors. The poster will also include results demonstrating
preferential CD47 target engagement by ADG153 in the tumor
microenvironment.
Details for the poster presentations include:
- Title: Initial results of a phase 1b/2 study of ADG126 (a
masked anti-CTLA-4 SAFEbody®) in combination with pembrolizumab (an
anti-PD-1 antibody) in patients with advanced/metastatic solid
tumors
Session Date: Tuesday, Apr 18, 2023
(abstract publication on April 14)Session Time: 9:00 AM - 12:30 PM
(Eastern time)Location: Poster Section 47Poster Board Number:
23Abstract Number: CT233
- Title: Interim results of a phase
1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody®) monotherapy
and in combination with toripalimab (an anti-PD-1 antibody) in
patients (pts) with advanced / metastatic solid tumors
Session Date: Tuesday, Apr 18, 2023
(abstract publication on April 14)Session Time: 9:00 AM - 12:30 PM
(Eastern time)Location: Poster Section 47Poster Board Number:
17Abstract Number: CT227
- Title: ADG153, a novel masked
anti-CD47 IgG1 SAFEbody, demonstrates strong in vivo anti-tumor
activities in preclinical solid tumor models and preferential CD47
target engagement in the tumor microenvironment
Session Date: Monday, Apr 17, 2023
(abstract publication on March 14)Session Time: 1:30 PM - 5:00 PM
(Eastern time)Location: Poster Section 23Poster Board Number:
8Abstract Number: 2930
The posters will be published on the company’s website
at www.adagene.com/pipeline/publications in accordance
with the AACR embargo policy.
About AdageneAdagene Inc. (Nasdaq: ADAG) is a
platform-driven, clinical-stage biotechnology company committed to
transforming the discovery and development of novel antibody-based
cancer immunotherapies. Adagene combines computational biology and
artificial intelligence to design novel antibodies that address
unmet patient needs. Powered by its proprietary Dynamic Precision
Library (DPL) platform, composed of NEObody™, SAFEbody®, and
POWERbody™ technologies, Adagene’s highly differentiated pipeline
features novel immunotherapy programs. Adagene has forged strategic
collaborations with reputable global partners that leverage its
technology in multiple approaches at the vanguard of science.
For more information, please visit:
https://investor.adagene.com. Follow Adagene on WeChat, LinkedIn
and Twitter.
SAFEbody® is a registered trademark in the United States, China,
Australia, Japan, Singapore, and the European Union.
Safe Harbor StatementThis press release
contains forward-looking statements, including statements regarding
ADG126 and ADG153, the potential implications of preclinical and
clinical findings of these product candidates, and Adagene’s
advancement of, and anticipated clinical development, regulatory
milestones and commercialization of Adagene pipeline candidates.
Actual results may differ materially from those indicated in the
forward-looking statements as a result of various important
factors, including but not limited to Adagene’s ability to
demonstrate the safety and efficacy of its drug candidates; the
clinical results for its drug candidates, which may not support
further development or regulatory approval; the content and timing
of decisions made by the relevant regulatory authorities regarding
regulatory approval of Adagene’s drug candidates; Adagene’s ability
to achieve commercial success for its drug candidates, if approved;
Adagene’s ability to obtain and maintain protection of intellectual
property for its technology and drugs; Adagene’s reliance on third
parties to conduct drug development, manufacturing and other
services; Adagene’s limited operating history and Adagene’s ability
to obtain additional funding for operations and to complete the
development and commercialization of its drug candidates; Adagene’s
ability to enter into additional collaboration agreements beyond
its existing strategic partnerships or collaborations, and the
impact of the COVID-19 pandemic on Adagene’s clinical development,
commercial and other operations, as well as those risks more fully
discussed in the “Risk Factors” section in Adagene’s filings with
the U.S. Securities and Exchange Commission. All forward-looking
statements are based on information currently available to Adagene,
and Adagene undertakes no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as may be required
by law.
Investor & Media Contact:
Ami Knoefler
650-739-9952
ir@adagene.com
Adagene (NASDAQ:ADAG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adagene (NASDAQ:ADAG)
Historical Stock Chart
From Apr 2023 to Apr 2024